The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.
UK-based bispecific immunotherapy developer Immunocore has filed to raise up to $100m in an initial public offering that will enable pharmaceutical firms Eli Lilly and WuXi AppTec to exit. Immunocore is developing T-cell engaging receptors (TCR) antibody treatments for cancer, infectious and autoimmune diseases, and will use some of the IPO takings to advance lead…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.